Cytomx Therapeutics
Highly Engaged Employees
Highly Engaged EmployeesBusiness Services · California, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
151 Oyster Point Blvd Ste 400, South San...Phone Number
(650) 515-3185Website
www.cytomx.comRevenue
$18.3 MillionStock Symbol
CTMXIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
2
1
1
2
2
1
About Cytomx Therapeutics
CytomX Therapeutics is a NASDAQ-listed clinical-stage biopharmaceutical company dedicated to revolutionizing oncology treatments. The company utilizes its proprietary Probody® therapeutic platform to develop conditionally activated, masked biologic drugs. This technology is designed to localize drug activity specifically to the tumor microenvironment, thereby increasing efficacy against cancer while minimizing damage and toxicity to healthy tissues throughout the rest of the body. CytomX's robust pipeline includes Probody drug conjugates (ADCs) and T-cell engaging bispecific antibodies, targeting unmet needs in solid tumors and other cancers. The company operates on a hybrid business model, generating revenue through extensive R&D and milestone payments from major strategic partnerships with pharmaceutical leaders like Bristol Myers Squibb and Amgen.Explore more
Cytomx Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Cytomx Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Cytomx Therapeutics recently announced quarterly report
Check if Cytomx Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once Cytomx Therapeutics has new funding data
Congratulate Masked Content for being promoted to Masked Content at Cytomx Therapeutics
Check out if Cytomx Therapeutics is spiking on competitors!
Click to see if Cytomx Therapeutics had a recent Job posting/layoffs
Product Launch: Get notified when Cytomx Therapeutics launches new products
Cytomx Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to Cytomx Therapeutics
Compare insights from companies similar to Cytomx Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Cytomx Therapeutics
$18.3M
51-200
Public
$341.2M
2008
YC
Yu-Waye ChuSenior Vice President, Chief Medical Officer
$35M
51-200
Public
$425M
2015
Kendra AdamsChief Financial Officer & Head Corporate Affairs & Principal Accounting Officer
Company Profile Activity
Activity Insights
Cytomx Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Cytomx Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Cytomx Therapeutics.
Cytomx Therapeutics financials insights
Gather financial insights about Cytomx Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2010
Series A
$1.3M
2012
Series B
$41M
2015
Multiple Rounds
$182M
2018
Stock Offering
$116.9M
Cytomx Therapeutics Tech Stack
A closer look at the technologies used by Cytomx Therapeutics
See more technologies
Most Recent Scoops
Earnings
Cytomx Therapeutics has reported a cash, equivalents, and investments balance of $330.3 million as of June 30, 2026, compared to $346.7 million as of March 31, 2026, with the company projecting cash runway to at least H2 2028, excluding an additional $37 million payment received from Regeneron in July 2026.
Accounting, Financial Reporting, Business Finance, Finance
Project
plans to initiate a new Phase I/II trial in Q4, evaluating escalating doses of Varseta-M in combination with bevacizumab, 5-fluorouracil, and leucovorin in second-line colorectal cancer patients, with the goal of replacing irinotecan with Varseta-M in earlier-line colorectal cancer treatment.
Medical Research, Pharmaceuticals, Clinical Operations
New Hire
Executive Move
Executive Moves, New Hire
Project
reported that the March 2026 Varseta-M expansion phase update showed no evidence of EpCAM-mediated toxicities, a very low incidence of hematologic toxicities, no interstitial lung disease.
Medical Research
Project
Medical Research, Pharmaceuticals
Cytomx Therapeutics News & Media
CytomX Therapeutics Announces FDA Fast Track Designation for Varsetatug masetecan (“Varseta-M”) for Relapsed/Refractory Metastatic Colorectal Cancer (R/R mCRC)
- Fast Track Designation follows encouraging Phase 1 data that were previously reported for R/R mCRC -CytomX Therapeutics, Inc. (CTMX) Q2 2026 Earnings Call Transcript
CytomX Therapeutics, Inc. (CTMX) Q2 2026 Earnings Call August 6, 2026 5:00 PM EDTCompany ParticipantsChris Ogden - SVP, CFO & SecretarySean McCarthy -...CytomX Therapeutics Announces Q2 2026 Financial Results and Provides Business Update
Varsetatug masetecan (“Varseta-M”) Program:CytomX Therapeutics Appoints Alejandra Carvajal as Chief Legal Officer
SOUTH SAN FRANCISCO, Calif., Aug. 03, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced the appointment of Alejandra Carvajal as Chief Legal Officer. In this role, Ms. Carvajal will support the Company’s strategic, operational, and pipeline initiatives.
Read more news
Top Business Services Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Cytomx Therapeutics
Sign Up For FreeTo access detailed company insights
CytomX Therapeutics is a NASDAQ-listed clinical-stage biopharmaceutical company dedicated to revolutionizing oncology treatments. The company utilizes its proprietary Probody® therapeutic platform to develop conditionally activated, masked biologic drugs. This technology is designed to localize drug activity specifically to the tumor microenvironme... Read More
